Argenx
ARGX
#425
Rank
S$70.60 B
Marketcap
S$1,134
Share price
-1.30%
Change (1 day)
38.50%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): S$1.25 Billion

According to Argenx 's latest financial reports the company's current earnings are S$3.60 Billion. In 2024 the company made an earning of S$0.11 Billion, an increase over its 2023 earnings that were of -S$0.4 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) S$1.25 B1038.23%
2024 S$0.11 B-127.97%
2023 -S$0.4 Billion-58.25%
2022 -S$0.95 Billion
2019 -S$0.26 Billion124.86%
2018 -S$0.12 Billion131.81%
2017 -S$49.27 Million54.9%
2016 -S$31.81 Million33.71%
2015 -S$23.79 Million12.93%
2014 -S$21.07 Million46.39%
2013 -S$14.39 Million